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Aqueous solubility of a drug can be a critical limitation to its oral absorption. Lipo-
philic molecules, especially those belonging to the biopharmaceutics classification sys-
tem (BCS) class II and IV, dissolve slowly, poorly and irregularly, and hence pose serious
delivery challenges, like incomplete release from the dosage form, poor bioavailability,
increased food effect, and high inter-patient variability (1). Many solubilization techni-
ques have been described that either change the nature of the solvent environment (co-
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Irbesartan (IBS) is a hydrophobic drug with poor aque-
ous solubility and dissolution rate. Solid dispersions (SDs)
of IBS were prepared with both small molecules (tartaric
acid and mannitol) and polymeric additives (polyvinyl-
pyrrolidone, PVP, and hydroxypropyl methylcellulose,
HPMC). A 9.5 and 7 folds enhancement in solubility over
the crystalline form (14.6 mg mL–1) was observed for tar-
taric acid (138 mg mL–1) and PVP (103 mg mL–1), respec-
tively. Powder X-ray diffraction confirmed that IBS exis-
ted in the glassy state in all cases, even with excipients
having low glass transition temperature. Thermal methods
(differential scanning calorimetry and hot stage micros-
copy) were used to evaluate the miscibility of the drug
and additives. These techniques suggested that tartaric
acid led to generation of »amorphous solutions« in con-
trast to »amorphous suspensions« in other three cases.
The in vitro dissolution of IBS depended on the additive
load and increased with increasing concentration in the
case of tartaric acid, an acidifying excipient. The results
indicate the suitability of even small molecules for pro-
viding solubility benefits, which can be attributed to the
good glass forming ability and reasonable ability of IBS
to remain in the glassy state.
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-solvent systems, emulsions, micellization) or the chemical identity of the dissolved sol-
ute (salt formation, complexation, pro-drugs) (2).
Alteration of the solid state at the particle or molecular level involves a physical
change in the drug and is an attractive option for improving drug solubility (3).
Particle size reduction by micronization or nanonization can enhance the dissolu-
tion rate; however, the apparent solubility remains unaltered. At the molecular level, poly-
morphs offer a limited solubility advantage because of a small difference in free energy
(4). In contrast, amorphous systems with excess thermodynamic properties and lower
energetic barrier can offer significant solubility benefits (4). This solubility benefit can be
further enhanced by preparing solid dispersions (SDs). SDs contribute by slowing devitri-
fication, enhancing wettability and modulating the properties of the solvent (5).
The aim of the present study was to examine the solubility and dissolution proper-
ties of SDs of irbesartan (IBS), prepared with small molecules such as tartaric acid and
mannitol and polymeric additives like polyvinylpyrrolidone (PVP) and hydroxypropyl
methylcellulose (HPMC). IBS, 2-butyl-3-[[29-(1H-tetrazol-5-yl) [1,19-biphenyl]-4-yl] me-
thyl]1,3-diazaspiro[4,4] non-1-en-4-one (Fig. 1), is a potent long acting non-peptide AII
receptor antagonist used in the treatment of hypertension (6). IBS was chosen as a model
candidate because of its low dissolution rate and solubility-limited bioavailability (7).
We have previously reported that the amorphous form of IBS improves solubility over
the crystalline form (7).
EXPERIMENTAL
Materials
IBS (purity > 99%) was gift of Dr Reddy’s Labs (India). All high-performance liquid
chromatography (HPLC) solvents were of HPLF grade and procured from Merck (Ger-
many), tartaric acid (DL) was obtained from s.d. Fine-chem Ltd. (India), mannitol from
Qualigens (India), poly(vinylpyrrolidone) (PVP) K30 was obtained from ISP Technolo-
gies (USA), and hydoxypropyl methylcellulose (HPMC) K100LV was obtained from Co-
lorcon Asia Pvt. Ltd. (India). All other chemicals were of analytical grade. The materials
were used as received without any further purification.
Preparation of amorphous IBS by quench cooling
Amorphous IBS was prepared by melting the drug in a stainless steel beaker at
200 °C and subsequent quench cooling of the melt over crushed ice. The quench-cooled
product was ground, sieved (BSS No. 60, mesh size 250 mm) and found to be amorphous
by powder X-ray diffraction (PXRD) immediately after preparation. HPLC analysis (me-
thod described below) confirmed that no degradation had occurred during the procedure.
Generation of solid dispersions of IBS
As discussed in previous section, quench cooling was used for preparation of SDs
of IBS. Temperature was controlled in dependence on the melting temperature of the
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drug/excipients. Physical mixtures of the drug and additives were prepared by geome-
tric mixing, by triturating using the mortar and pestle. The quench-cooled product was
ground, sieved (BSS No. 60 mesh size, 250 mm) and used immediately after preparation.
Initially, 20% (m/m) of the excipient (tartaric acid, mannitol, PVP and HPMC) was used.
The effect of the concentration of tartaric acid and PVP (selected excipients) was also
studied.
Powder X-ray diffraction (PXRD)
PXRD patterns of freshly prepared powdered samples (under controlled tempera-
ture and humidity conditions) were recorded at room temperature on Bruker’s D8 Ad-
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Fig. 1. Chemical structure of IBS and additives: a) IBS, b) tartaric acid, c) mannitol, d) PVP, e) HPMC.
vance diffractometer (Germany) with CuKa radiation (1.54 Å), at 40 kV, 40 mA, passing
through a nickel filter with a divergence slit (0.5°), antiscattering slit (0.5°), and receiving
slit (1 mm). The diffractometer was equipped with a 2q compensating slit and was cali-
brated for accuracy of peak positions with a silicon pellet. Samples were mounted either
on a 25-mm holder made of polymethyl methacrylate (PMMA) or a zero background
small sample holder, depending on sample size, and were subjected to X-ray powder
diffraction analysis in continuous mode with a step size of 0.01° and step time of 1 sec-
ond over an angular range of 3 to 40° 2q. Sample holders were rotated in a plane parallel
to their surface at 30 rpm during the measurements. Obtained diffractograms were ana-
lyzed with DIFFRACplus EVA (ver. 9.0) diffraction software.
Differential scanning calorimetry (DSC)
Thermal transitions were determined using a Mettler Toledo 821e DSC (Mettler To-
ledo, Switzerland) operating with version 5.1 of Stare software using (4–6 mg) samples
in aluminium pans with pierced lids at heating rates of 20 °C min–1 under nitrogen pur-
ge at 80 mL min–1. The instrument was calibrated for temperature and heat flow using
high purity indium and zinc standards.
Hot stage microscopy (HSM)
Thermal transitions were visually observed under a Leica DMLP polarized micro-
scope (Leica Microsystems, Germany) equipped with Leica LMW hot stage. Photomicro-
graphs were acquired using a Leica DC 300 camera and analyzed using Leica IM 50 (ver-
sion 1.20) software.
High performance liquid chromatography
The HPLC method for solubility and dissolution rate studies has been described
previously (6). All solubility and dissolution samples were analyzed on an HPLC system
(Shimadzu, Japan) using Lichrospher® 100 RP-18e (5 mm) (Merck, Germany) analytical
column under isocratic conditions at a flow rate of 0.7 mL min–1 at 25 °C. Injection vol-
ume 10 mL and effluent were monitored at 275 nm. The mobile phase was 10 mmol L–1
potassium dihydrogen orthophosphate/methanol/acetonitrile (15:75:10) (pH 2.5).
In vitro dissolution studies
Dissolution experiments of crystalline, amorphous and SD samples were carried out
in triplicate with a United States Pharmacopeia Apparatus I (basket-type) (TDT-08L,
Electrolab, India), employing 900 mL of deionized water and 0.1 mol L–1 HCl, at a tem-
perature of 37 ± 0.5 °C, at rotational speed of 100 rpm. Sample mass maintaining the sink
conditions (i.e., three times the solubility) was filled into hard gelatin capsule shells. At
predetermined intervals (5, 15, 30, 60, 90, 120, 240, 360 and 480 min), samples were with-
drawn (with replacement of equal volume of an pre-warmed medium into the vessel),
filtered, appropriately diluted and analyzed for drug concentration using HPLC. It was
first confirmed that the method was specific for the analysis of IBS and additives did not
interfere with the drug. In vitro dissolution studies of SDs were also performed using
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different concentrations of excipients, tartaric acid and PVP [10, 20, 40, 50, 60 and 80%
(m/m)].
The effects of rotational speed (25, 50 and 100 rpm), sample fill mass in the capsule
and degassing of media on the dissolution rate were also studied.
Solubility studies
The dynamic solubility of crystalline, amorphous and various SDs of IBS was deter-
mined by adding excess solid (150 mg) to 100 mL deionized water placed in stoppered
conical flasks, pre-equilibrated to 37 ± 0.5 °C. The flasks were mechanically shaken in a
shaking water bath (SW 23, Julabo Labortechnik GmbH, Germany) at 100 rpm. At pre-
-determined intervals, an aliquot was withdrawn, filtered through a 0.45-mm syringe fil-
ter, diluted and analyzed by HPLC. Simultaneously, the solid phase was analyzed by
PXRD.
Solubility studies of the physical mixture (prepared by geometric mixing) of drug-
-excipient and in solution of 20% (m/m) excipient in water were performed.
RESULTS AND DISCUSSION
IBS is a non-polar compound with a partition coefficient (octanol/water) of 10.1 at
pH 7.4, and low aqueous solubility (< 0.1 mg mL–1 in water at 25 °C). The crystalline
form A crystallizes with 2 hydrophobic channels containing aliphatic chains, leading to
weak solubility and strong aggregation in water. Previous work by the authors (6) illus-
trated a 2.5 fold higher »apparent« solubility of amorphous IBS over its crystalline pha-
se. Lower heat of solution (DHs) for amorphous IBS (–12.6 kJ mol–1) in comparison to
crystalline form (–37.6 kJ mol–1), absence or reduced crystal packing energy and higher
Gibb’s free energy (DG) indicated the ease and spontaneity of IBS molecules to leave the
disordered amorphous system and be molecularly dispersed in the solvent (8).
Conventionally, this enhanced solubility of the amorphous system would translate
into an increased dissolution rate. However, dissolution rate of amorphous IBS was lo-
wer than the dissolution rate of the crystalline form of IBS, in water and in 0.1 mol L–1
HCl (Fig. 2a). Visual observation revealed that the amorphous material had formed a
hard plug that prevented penetration of water to deeper layers (Fig. 2b). This was con-
firmed by the cross sectional view of the plug, wherein the outer surface was wet, and
the inner portion was found to be comparatively dry. The residual material at the end of
the eight hours long dissolution experiment was characterized by PXRD and polarized
light microscopy. The outer sample surface of IBS indicated partial crystallization as it
was evident from the appearance of sharp diffraction peaks. The sample core essentially
retained the amorphous nature (Fig. 2c). Similar observations have been made previously
with drugs like ritonavir and carvedilol wherein amorphous forms exhibited incomplete
release in comparison with the crystalline form; however, generation of SD improved
the dissolution rate (10,11). Higher apparent solubility of amorphous IBS at all pH val-
ues and a higher intrinsic dissolution rate (6) suggested that IBS could be a good candi-
date for dissolution rate improvement through SD formation.
261
G. Chawla and A. K. Bansal: Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-
-polymeric hydrophilic additives, Acta Pharm. 58 (2008) 257–274.
262
G. Chawla and A. K. Bansal: Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-











0 5 10 30 60 90 120 240 360 480
Time (min)
Crys capsule in water
Crys capsule in 0.1 mol L HCl
–1
Amor capsule in water































Fig. 2. In vitro dissolution-time profile of amorphous IBS: a) concentration time profile of crystalline
and amorphous IBS, b) plug formed in amorphous IBS in dissolution media, c) PXRD pattern of re-
sidual dissolution samples.
Amorphous materials have the ability to form molecular level single-phase disper-
sions with pharmaceutical excipients. These »amorphous alloys« permit creation of cus-
tom pharmaceuticals with unique properties by selection of appropriate interacting ex-
cipients (12). Numerous reports have cited dissolution rate improvement of poorly
soluble drugs through production of SDs using various hydrophilic carriers, such as po-
lyvinylpyrrolidone, hydroxypropyl methylcellulose, sugars, and mannitol (13–16). Dis-
persions of IBS were formed using two non-polymeric excipients, tartaric acid and ma-
nnitol, and two polymeric excipients, PVP and HPMC.
Fig. 3a exhibits the needle-shaped crystals of the drug. Amorphous material on the
other hand exhibits irregularly shaped birefringent particles. SDs of IBS were formed us-
ing quench cooling, which led to generation of a non-birefringent glassy material ob-
served under polarized light (Fig. 3b). All freshly prepared dispersions, except the one
with mannitol, exhibited a halo pattern in PXRD, thus confirming their amorphous na-
ture. Comparison of PXRD patterns of IBS-mannitol dispersions revealed that the peaks
matched that of mannitol and peaks corresponding to IBS were absent (Fig. 3c). Hence,
it can be inferred that IBS was present in the amorphous state in the dispersion and ma-
nnitol was in the crystalline state. Similar behavior has been reported for mannitol with
other drug substances in earlier studies (14, 17).
DSC analysis of crystalline IBS showed a single sharp fusion endotherm in the tem-
perature range of 183–190 (± 0.5) °C (DHf = 107 ± 2 J g–1) at a heating rate of 20 °C min–1.
Quench-cooled IBS exhibited a glass transition event at 71.7 ± 1.0 °C (onset Tg) and no
other exothermic peak of crystallization or endothermic peak of melting was observed.
Even when heated at a slow rate of 1 °C min–1, amorphous IBS did not crystallize spon-
taneously, thus suggesting lack of crystallization tendency of amorphous IBS. IBS exhib-
ited a Tg/Tm of 0.75 and is expected to be a relatively good glass former (10).
The nature of SD was also studied using HSM and DSC by performing studies on
both physical mixtures and SDs. In DSC, changes in the melting endotherm of the drug
and single Tg at a temperature between Tg values of both components is evidence for
formation of a miscible system (18). SDs can thus be classified as an »amorphous solu-
tion« (with single Tg), »amorphous suspension« (two Tgs) or crystalline suspension (Tg
and melting event).
Unlike mannitol, tartaric acid exhibited complete miscibility with molten IBS. How-
ever, these events cannot be resolved with DSC as the melt endotherms may be a mix-
ture of the heat of fusion and heat of solution (Fig. 3d). HSM clearly allowed visualiza-
tion of the events, melting and dissolution of one component in the melt of the other
(Fig. 3e). On a hot stage microscope, tartaric acid melted in the range of 180–207 °C. In
the presence of IBS, a single event of melting of both components was observed at
170–180 °C, resulting in a clear melt. This indicated miscibility of the two components.
In DSC, quench cooled IBS-tartaric acid dispersions showed a single Tg at 79 °C (Tgonset),
thus proving formation of an »amorphous solid solution«. However, the glass transition
event of this phase was observed at a temperature higher than the temperature expected
based on the composition (Table I). Such an increase in Tg has been observed previously
as a result of ionic and heteromolecular interactions (14, 19, 20). Theoretical Tg of the
drug-additive mix (Table I) was calculated using the Gordon-Taylor/Kelley-Bueche
equation (21):
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With mannitol, molten additive gave rise to an immiscible liquid phase within the
molten drug (Figs. 3f,g). This immiscibility was observed in HSM as droplets of manni-
tol within the melt of IBS. In addition, mannitol recrystallizes quickly on a hot stage mi-
croscope upon melt cooling (Fig. 3h), thus giving sharp peaks in PXRD. Pure mannitol
exhibited a sharp melting endotherm in the temperature range of 164–176 °C. Two Tgs,
at 59 and 71 °C (Fig. 3i) in the case of quench cooled IBS-mannitol dispersions suggested
the formation of an »amorphous suspension«. With time, when stored under room tem-
perature and humidity, this dispersion can be categorized as a »crystalline suspension«
containing amorphous drug and crystalline mannitol. Similar behavior of D-mannitol has
been observed by other authors with drugs such as sulphonamides, tolbutamide, isopro-
pylantipyrin and oxazepam (17).
Polymeric excipients PVP and HPMC did not mix with the drug melt in their mol-
ten state. In DSC, no melting endotherms were observed with pure PVP and HPMC due
to their amorphous nature. Immiscibility was observed on both HSM and DSC. Droplets
of softened PVP were observed in the melt of the drug (Fig. 3j), while solid particles of
HPMC were entrapped in the melt droplets of the drug (Fig. 3k). HPMC remained as a
solid until a temperature of 230 °C. In quench cooled dispersions Tgs were observed at
about 81 °C for IBS and near 167 °C for the excipients (Fig. 3l). High viscosity of poly-
mers has been reported previously to limit the miscibility of drugs with polymers (22).
These dispersions can be also classified as »amorphous suspensions« containing two,
partial or complete, amorphous phases (23).
IBS, a hydrophobic molecule, achieves an equilibrium aqueous solubility of 14.6 mg
mL–1 in about 480 min. The crystalline material adhered to the walls of the flask and
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Table I. Tg of additives and theoretical Tg of SDs
Additive Tg (°C) Theoretical Tgmix of SD (°C) Peak concentration (mg mL–1)
Tartaric acid 18 63 138
Mannitol 11 60 55
PVP 168 87 103
HPMC 150–180 87a 81
a Average Tg taken
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floated on the surface of medium. Glassy IBS, on the other hand, sank in water in about
10 min and exhibited enhanced peak solubility of 36.4 mg mL–1. This initial solubility
peak value started to drop after 60 min, became equivalent to the crystalline form in 120
min and in 480 min reduced to 10 mg mL–1 (73% drop from peak), which is even less
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Fig. 3. Thermal and PXRD characterization of crystalline, quench cooled SD and IBS-additive (20%,
m/m) physical mixture: a) crystalline IBS under HSM, 100x, RT, b) SD prepared using quench cool-
ing under HSM, 100x, RT, c) PXRD of SD and mannitol (dashed boxes highlight the peaks of ma-
nnitol in IBS-mannitol SD), d) IBS-tartaric acid physical mixture under HSM, 200x, 200 °C, e) DSC
curve of IBS-tartaric acid physical mixture and SD, f) IBS-mannitol under HSM, 200x 190 °C, g)
IBS-mannitol under HSM, 200x, 200 °C, h) IBS-mannitol cooled after melting under HSM, 200x, 185
°C (inset shows a magnified view at 630x), i) DSC curve of IBS-mannitol physical mixture and SD, j)
IBS-PVP under HSM, 200x, 203 °C, k) IBS-HPMC under HSM, 200x, 223 °C, l) DSC curve of
IBS-PVP SD.
than the pure crystalline form, due to formation of the lower solubility polymorph-form
B (6). SDs prepared using both types of excipients showed significant enhancement in
solubility over the crystalline and amorphous forms (Fig. 4). As observed from Fig. 4,
maximum enhancement in solubility was achieved using tartaric acid (solubility peak
138 mg mL–1 in 90 min). Mannitol exhibited the least improvement in solubility peak (55
mg mL–1 in 30 min), but was still higher than amorphous or crystalline IBS. In case of
polymeric excipients, PVP (solubility peak 103 mg mL–1 in 240 min) exhibited higher solu-
bility than HPMC (solubility peak 81 mg mL–1 in 60 min). Even at a concentration of 20%
(m/m), a marked solubility advantage was observed with tartaric acid and PVP. Another
interesting observation relating to polymeric excipients was the duration of solubility
peak. The drop in solubility values after attaining »metastable« solubility was less in poly-
meric dispersions compared to dispersions of non-polymeric molecules. Polymeric ex-
cipients exhibited a negligible drop from the solubility peak values (PVP 1.2; HPMC 1.1
folds) in contrast to the 8.2 fold drop from the solubility peak value in 480 min in pure
amorphous IBS.
Excipients in SDs can affect solubility primarily by two mechanisms: (i) capacity to
stabilize amorphous drug against water-induced crystallization, or (ii) specific contribu-
tion towards the solubilization process.
Water, which is a strong plasticizer, leads to reduction in Tg of the system causing
devitrification. Polymeric materials have been reported to have higher Tg values (PVP
168 °C, HPMC 168 °C) and would therefore act as better stabilizers compared to small
molecules that have lower Tg values (17). The high Tg values of polymers PVP and HPMC
may thus induce an anti-plasticization effect along with improved wettability due their
hydrophilic nature. Polymers may help in maintaining supersaturation by coating and
passivating small embryos to arrest growth by preventing condensation of drug molecu-
les onto the surface embryos (24). This may be the probable reason for lower drop in solu-
bility from the peak value in case of dispersions prepared using polymers. Both PVP and
267
G. Chawla and A. K. Bansal: Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-



























profiles of crystalline, amor-
phous and SDs of IBS [us-
ing 20% (m/m) of the exci-
pient]. SD bars for n = 3.
HPMC showed almost similar solubility profiles. Moreover, being hydrophilic in nature
the polymers would not act as rate controlling parameters for dissolution.
Small molecules with low Tg values are not expected to stabilize the amorphous sy-
stem against water-induced recrystallization. Tartaric acid was found to decrease the pH
of the solution [pH of water after addition of 20% (m/m) tartaric acid was 2.27, i.e. a
drop of about 6.7 units] and as IBS exhibited improved solubility at lower pH values (6),
solubilization would be aided by this drop in pH. As reported earlier, at low pH values
IBS exhibited high solubility and after attaining the peak, a plateau was achieved with
no drop in solubility. A similar case was that of tartaric acid and only a 1.7 fold drop in
solubility was observed. In contrast, no change in pH was observed with the other exci-
pient-mannitol. Sugars and highly soluble polyolic materials act as »water structure for-
mers«. These substances have been reported to strengthen the intermolecular hydrogen
bonding in water, making it more hydrophobic, and thus favor the dissolution of a poor-
ly hydrosoluble drug (25).
Two additives, namely tartaric acid and PVP, were selected as representatives of
small molecules and polymers, respectively. The additive concentration was found to play
a significant role in the solubility of dispersions, especially for tartaric acid. In case of
tartaric acid SDs, it was observed that the concentration of tartaric acid controlled both
the time taken to reach the peak and the peak solubility values (Fig. 5a). Peak solubility
and time taken to achieve this peak was found to increase with the increasing concentra-
tion of tartaric acid. In addition, pH values were dependent on concentration of tartaric
acid, with the highest of 2.33 with 10% and a minimum of 1.96 with 80% (m/m) of tar-
taric acid. This dependence of performance on the content of additive in tartaric acid
dispersions may be due to the pH shift caused by the acid. A marginal change in pH
may be sufficient to influence the solubility of IBS owing to its strong pH dependent solu-
bility, as observed in the previous report (6). On the other hand, in the case of PVP, dif-
ferences in solubility were observed at 20% (m/m) (105 mg mL–1 in 240 min) and 80%
(m/m) (169 mg mL–1 in 360 min). Solubility values in PVP at different concentrations re-
mained within a close range, with a sudden rise seen at 80% (m/m).
PXRD of dispersions was performed and it was observed that IBS was amorphous
at all concentrations. Halo pattern was observed in all SDs; however, in dispersions con-
taining more than 40% (m/m) tartaric acid, few diffraction peaks of low intensity were
observed. The peaks increased both in number and intensity with the increase in concen-
tration. IBS was present in amorphous form at all concentrations since no peaks of IBS
were observed in PXRD.
The PXRD and HSM studies suggested that tartaric acid was miscible with IBS at all
concentrations, but at high concentrations, tartaric acid crystallized on cooling. How-
ever, being a relatively stable molecule in the glassy state, IBS does not crystallize out
even with a low Tg (18 °C) substance like tartaric acid. Also, the absence of endothermic
peak in DSC corresponding to IBS melting indicated that the drug was dispersed amor-
phously. In the case of PVP, a halo pattern was observed in all cases. However, on the
hot stage microscope, at concentration higher than 20% (m/m), PVP did not melt and re-
mained as solid particles dispersed in the drug melt.
The relative contribution of additives, present either in solid phase (in drug-addi-
tive mixtures, PM) or in solution (in pre-dissolved state in water, phase solubility), was
ascertained by studying the solubilities of the physical mixtures and by dissolving the
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additive in water. Fig. 6 shows the solubility values of the physical mixture and in pre-
-dissolved solutions of tartaric acid and PVP at a concentration of 20% (m/m). Both ad-
ditives led to a significant increase in solubility of both crystalline and amorphous IBS.
In the case of tartaric acid, the »acidifying« excipient, physical solubility and phase solu-
bility values followed the order: amorphous phase solubility > amorphous PM > SD >
crystalline phase solubility > crystalline PM indicating that the amorphous state of the
drug has some role to play in interaction of ionic groups of the excipient. This also con-
firmed the acidifying nature of tartaric acid and suggested that its role as an acidifier is
less pronounced when present in molecularly dispersed state with the drug in SD. The
solubility values were considerably low in crystalline PM and crystalline phase solubil-
ity. The drop in solubility peak was faster in amorphous phase solubility (30 min) com-
pared to SD and amorphous PM (90 min). The trend was quite different with the poly-
meric excipient PVP. Highest solubility was observed in SD and the lowest with crystal-
line PM. Amorphous phase solubility, crystalline phase solubility and amorphous PM
exhibited almost similar values. This further confirmed the stabilization role (ability to
keep the drug in amorphous form) played by high Tg excipients in their solid state.
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Fig. 5. Solubility profiles of
SDs with different concen-
trations of additive: a) IBS-
-tartaric acid, b) IBS-PVP SD
(SD bars for n = 3).
Dissolution studies at different concentrations of solid dispersions were carried out
in 0.1 mol L–1 HCl. The trend was similar to solubility studies and the percentage relea-
sed increased with increasing concentration of tartaric acid (Fig. 7). The percentage re-
leased was more than that of tartaric acid amorphous form (24% released in 360 min)
even at the concentration of 10% (m/m) (31% released in 360 min). The highest percent-
age release was observed at 80% (m/m) (85% in 360 min) and more than 75% release was
seen within 15 min. The release of IBS was faster in the initial phases of dissolution at
high concentrations of tartaric acid (60 and 80%, m/m). In the case of PVP, 10 and 20%
concentrations exhibited maximum release of 59 and 71%, respectively, in 360 min (Fig.
7). Unlike tartaric acid, also in PVP a gradual increase was seen over the entire period of
dissolution at all concentrations. No devitrification to crystalline form was observed in
either case during the dissolution studies. The problem of plug formation seen in the
case of pure amorphous form was not observed at concentrations higher than 40%
(m/m) of the excipient.
A number of mechanisms have been proposed for the increase in the dissolution
rate by SDs (5). These include reduction in size of the crystallite, solubilization effect of
the carrier, absence of aggregation of crystallites, improved wettability and dispersibility
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Fig. 6. Phase solubility and
physical mixture solubility
of IBS with: a) tartaric acid
and b) PVP (SD bars for n =
3).
of the drug from dispersion, drug dissolution in hydrophilic carrier, drug conversion to
amorphous state, and combination of the mentioned factors. The dissolution process can
be described by two distinct processes – the rate of the interfacial/solid-solvent reaction
leading to solubilization of the molecule and the rate of diffusion/transport of the sol-
vated molecule to the bulk of dissolution medium. The initial rise at higher concentra-
tions of tartaric acid and in PVP can be due to the decrease in interfacial tension between
the hydrophobic drug and the medium owing to the hydrophilic additive and local solu-
bility effect during early stages in the drug microenvironment.
CONCLUSIONS
SDs provide a practical means of further enhancing the solubility benefit achieved
using amorphous systems. IBS served as a model candidate for formation of solid solu-
tions or dispersions of amorphous IBS into a fast dissolving matrix. The »amorphous al-
loys« generated using small molecules like tartaric acid and mannitol or high molecular
mass polymers like PVP and HPMC led to a significant enhancement of solubility over
271
G. Chawla and A. K. Bansal: Improved dissolution of a poorly water soluble drug in solid dispersions with polymeric and non-








0 5 15 30 60 90 120 240 360
Time (min)
10% TA SD 20%TA SD 40% TA SD


















0 5 15 30 60 90 120 240 360
Time (min)
10% PVP SD 20% PVP SD 40% PVP SD











Fig. 7. In vitro dissolution
studies of SDs containing dif-
ferent concentrations of addi-
tives: a) tartaric acid and b)
PVP (SD bars for n = 3).
the crystalline form. In case of molecules that are relatively stable in their amorphous
state, it was anticipated that small molecules like acids and sugars could also be used for
generation of dispersions. Tartaric acid, by virtue of its pH altering capacity and manni-
tol by its water structure forming ability led to a significant improvement in solubility
over crystalline IBS. High Tg polymers like PVP and HPMC, apart from their antiplasti-
cization effect, increase the wettability and hydrophilicity of the system and maintain
the molecules in the disordered state for a longer period.
Significant opportunities lie in the field of amorphous pharmaceuticals. Through an
understanding of the relationship between the glassy behavior and product performan-
ce and a thorough insight into the thermodynamic and kinetic properties, it is possible
to commercially utilize these molecularly disordered systems in pharmaceuticals.
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S A @ E T A K
Pobolj{ana topljivost te{ko topljivog lijeka u ~vrstim disperzijama
s polimernim i nepolimernim hidrofilnim dodacima
GARIMA CHAWLA i ARVIND K. BANSAL
Irbesartan (IBS) je hidrofobni lijek te{ko topljiv u vodi koji se slabo osloba|a iz lje-
kovitih pripravaka. U radu je opisana priprava ~vrstih disperzija (SDs) IBS-a pomo}u
aditiva male relativne molekulske mase (vinska kiselina i manitol) i polimera (polivinil-
pirolidona, PVP, i hidroksipropil metilceluloze, HPMC). Koriste}i vinsku kiselinu i PVP
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topljivost je pove}ana 9,5 puta (138 mg mL–1), odnosno 7 puta (103 mg mL–1) u odnosu na
kristalini~nu formu (14,6 mg mL–1). Difrakcijom X-zrakama pra{kastog uzorka potvr|e-
no je da je IBS uvijek u staklastom stanju, pa i s pomo}nim tvarima koje pri niskim tem-
peraturama prelaze u staklasto stanje. Termi~ke metode (diferencijalna pretra`na kalori-
metrija i mikroskopija s vru}om plo~om) kori{tene su za procjenu sposobnosti mije{anja
lijeka s aditivima. Rezultati ukazuju da vinska kiselina stvara amorfnu otopinu, a ostale
tvari amorfne suspenzije. Osloba|anje IBS-a in vitro ovisi o koli~ini aditiva i raste s pove-
}anjem koncentracije vinske kiseline, (kisele pomo}ne tvari). Pobolj{anje topljivosti do-
datkom malih molekula mo`e se pripisati sposobnosti prelaska IBS-a u staklasto stanje i
sposobnosti zadra`avanja u tom stanju.
Klju~ne rije~i: irbesartan, ~vrsta disperzija, amorfno stanje, topljivost, osloba|anje
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